DOCSLIB.ORG

Mouse Cracr2a Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Cracr2a Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Cracr2a Knockout Project (CRISPR/Cas9) Objective: To create a Cracr2a knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Cracr2a gene (NCBI Reference Sequence: NM_001033464 ; Ensembl: ENSMUSG00000061414 ) is located on Mouse chromosome 6. 7 exons are identified, with the ATG start codon in exon 2 and the TAA stop codon in exon 7 (Transcript: ENSMUST00000071563). Exon 2~5 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 2 starts from the coding region. Exon 2~5 covers 70.22% of the coding region. The size of effective KO region: ~7703 bp. The KO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 5 7 Legends Exon of mouse Cracr2a Knockout region Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 2 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section downstream of Exon 5 is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. The gRNA site is selected outside of these tandem repeats. Page 3 of 8 https://www.alphaknockout.com Overview of the GC Content Distribution (up) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(26.9% 538) | C(23.35% 467) | T(28.65% 573) | G(21.1% 422) Note: The 2000 bp section upstream of Exon 2 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution (down) Window size: 300 bp Sequence 12 Summary: Full Length(2000bp) | A(25.6% 512) | C(24.55% 491) | T(25.9% 518) | G(23.95% 479) Note: The 2000 bp section downstream of Exon 5 is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 4 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr6 + 127601864 127603863 2000 browser details YourSeq 88 620 766 2000 84.5% chr2 - 14974852 14975000 149 browser details YourSeq 79 650 804 2000 87.1% chr1 - 84950927 84951087 161 browser details YourSeq 79 628 739 2000 85.8% chr18 + 77588725 77588838 114 browser details YourSeq 77 632 730 2000 88.9% chr2 - 49873757 49873855 99 browser details YourSeq 76 599 745 2000 88.8% chr2 + 143769808 143770341 534 browser details YourSeq 72 654 762 2000 83.5% chr16 + 20602434 20602544 111 browser details YourSeq 71 650 754 2000 79.8% chr8 + 78646303 78646396 94 browser details YourSeq 71 641 738 2000 86.8% chr5 + 126760736 126760839 104 browser details YourSeq 71 645 757 2000 79.5% chr1 + 39998210 39998321 112 browser details YourSeq 70 640 821 2000 92.7% chr7 + 126320063 126320460 398 browser details YourSeq 69 645 739 2000 86.4% chr10 + 45317484 45317578 95 browser details YourSeq 67 650 762 2000 87.7% chrX + 94307557 94307671 115 browser details YourSeq 66 611 739 2000 76.0% chr11 - 117145896 117146026 131 browser details YourSeq 65 627 717 2000 85.8% chr8 - 109753556 109753646 91 browser details YourSeq 65 611 721 2000 91.2% chr7 - 134076518 134076629 112 browser details YourSeq 65 646 727 2000 90.3% chr4 - 150726709 151140331 413623 browser details YourSeq 65 677 766 2000 86.7% chr16 - 21392238 21392328 91 browser details YourSeq 64 650 732 2000 89.5% chr16 + 97482519 97482600 82 browser details YourSeq 63 691 769 2000 91.2% chr4 - 47252484 47252844 361 Note: The 2000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 2000 1 2000 2000 100.0% chr6 + 127611534 127613533 2000 browser details YourSeq 56 192 259 2000 95.3% chr13 - 38577304 38577427 124 browser details YourSeq 55 192 254 2000 95.3% chr9 + 22828178 22828252 75 browser details YourSeq 53 192 256 2000 91.4% chr2 + 58403078 58403140 63 browser details YourSeq 52 192 256 2000 93.6% chr10 - 78111195 78111299 105 browser details YourSeq 49 192 248 2000 94.5% chr8 - 113786086 113786144 59 browser details YourSeq 48 194 263 2000 81.2% chr2 - 76853292 76853347 56 browser details YourSeq 40 194 252 2000 95.6% chr9 + 45404683 45404741 59 browser details YourSeq 39 194 240 2000 93.2% chr8 - 81577706 81577762 57 browser details YourSeq 37 162 220 2000 97.5% chr14 - 116129159 116129300 142 browser details YourSeq 37 192 234 2000 95.2% chr11 - 103124937 103124979 43 browser details YourSeq 37 197 238 2000 95.3% chr19 + 51581807 51581858 52 browser details YourSeq 36 193 232 2000 97.5% chr5 + 117003509 117003552 44 browser details YourSeq 34 192 226 2000 100.0% chr5 - 146725720 146725878 159 browser details YourSeq 34 1647 1721 2000 97.3% chr11 - 41454570 41454764 195 browser details YourSeq 34 1434 1468 2000 100.0% chr7 + 98225198 98225243 46 browser details YourSeq 32 1432 1464 2000 100.0% chr2 - 8608855 8608888 34 browser details YourSeq 32 192 228 2000 94.6% chr1 - 185078762 185078810 49 browser details YourSeq 32 194 228 2000 97.1% chr6 + 139384475 139384514 40 browser details YourSeq 32 1434 1465 2000 100.0% chr10 + 113609817 113609848 32 Note: The 2000 bp section downstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. Page 5 of 8 https://www.alphaknockout.com Gene and protein information: Cracr2a calcium release activated channel regulator 2A [ Mus musculus (house mouse) ] Gene ID: 381812, updated on 24-Oct-2019 Gene summary Official Symbol Cracr2a provided by MGI Official Full Name calcium release activated channel regulator 2A provided by MGI Primary source MGI:MGI:2685919 See related Ensembl:ENSMUSG00000061414 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Gm462; Gm1073; Efcab4b Expression Broad expression in colon adult (RPKM 2.8), lung adult (RPKM 2.7) and 16 other tissues See more Orthologs human all Genomic context Location: 6; 6 F3 See Cracr2a in Genome Data Viewer Exon count: 25 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 6 NC_000072.6 (127561062..127674234) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 6 NC_000072.5 (127527993..127579956) Chromosome 6 - NC_000072.6 Page 6 of 8 https://www.alphaknockout.com Transcript information: This gene has 3 transcripts Gene: Cracr2a ENSMUSG00000061414 Description calcium release activated channel regulator 2A [Source:MGI Symbol;Acc:MGI:2685919] Gene Synonyms Efcab4b, LOC243645, LOC381812 Location Chromosome 6: 127,561,338-127,674,248 forward strand. GRCm38:CM000999.2 About this gene This gene has 3 transcripts (splice variants), 248 orthologues, 1 paralogue, is a member of 1 Ensembl protein family and is associated with 1 phenotype. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Cracr2a-201 ENSMUST00000071563.4 1094 310aa ENSMUSP00000071494.4 Protein coding CCDS20566 Q3UP38 TSL:1 GENCODE basic Cracr2a-203 ENSMUST00000212051.1 7625 726aa ENSMUSP00000148569.1 Protein coding - A0A1D5RLZ8 TSL:5 GENCODE basic APPRIS P1 Cracr2a-202 ENSMUST00000201303.4 1267 No protein - Retained intron - - TSL:1 132.91 kb Forward strand 127.56Mb 127.58Mb 127.60Mb 127.62Mb 127.64Mb 127.66Mb 127.68Mb Genes (Comprehensive set... Cracr2a-203 >protein coding Cracr2a-202 >retained intron Gm43634-201 >lncRNA Cracr2a-201 >protein coding Contigs AC173480.1 > AC127373.3 > Regulatory Build 127.56Mb 127.58Mb 127.60Mb 127.62Mb 127.64Mb 127.66Mb 127.68Mb Reverse strand 132.91 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding Ensembl protein coding Non-Protein Coding RNA gene processed transcript Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000071563 51.96 kb Forward strand Cracr2a-201 >protein coding ENSMUSP00000071... MobiDB lite Low complexity (Seg) Coiled-coils (Ncoils) Superfamily EF-hand domain pair SMART EF-hand domain Pfam EF-hand domain PROSITE profiles EF-hand domain PROSITE patterns EF-Hand 1, calcium-binding site PANTHER PTHR22621 PTHR22621:SF27 Gene3D 1.10.238.10 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 310 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Load more

Recommended publications
  • 1.3 the CRAC Channel
    CRAC channel related proteins in the pathogenesis of inborn errors of immunity Laura Jane Rice Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds School of Medicine and Health Under the supervision of Rashida Anwar PhD and Sinisa Savic MD, PhD June 2021 Publication statement The candidate confirms that the work submitted is her own, except where work which has formed part of jointly-authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Laura Jane Rice to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2021 The University of Leeds and Laura Jane Rice ii Acknowledgements This work was funded by University of Leeds and CSL Behring (West Sussex, UK). I would like to thank my supervisors for their continued support. Rashida Anwar for her scientific knowledge, detail driven questions and help during the writing of this thesis. Sinisa Savic for his encouragement and clinical and immunology expertise. The Anwar group and Level 9 WTBB PhD students made this experience enjoyable with coffee and gin. I was fortunate to have collaborators with experience in CRAC channel research.
    [Show full text]
  • Large Rab Gtpases: Novel Membrane Trafficking Regulators with a Calcium Sensor and Functional Domains
    International Journal of Molecular Sciences Review Large Rab GTPases: Novel Membrane Trafficking Regulators with a Calcium Sensor and Functional Domains Takayuki Tsukuba 1,* , Yu Yamaguchi 1 and Tomoko Kadowaki 2 1 Department of Dental Pharmacology, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki 852-8588, Japan; [email protected] 2 Department of Frontier Oral Science, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto 1-7-1, Nagasaki 852-8588, Japan; [email protected] * Correspondence: [email protected] Abstract: Rab GTPases are major coordinators of intracellular membrane trafficking, including vesicle transport, membrane fission, tethering, docking, and fusion events. Rab GTPases are roughly divided into two groups: conventional “small” Rab GTPases and atypical “large” Rab GTPases that have been recently reported. Some members of large Rab GTPases in mammals include Rab44, Rab45/RASEF, and Rab46. The genes of these large Rab GTPases commonly encode an amino- terminal EF-hand domain, coiled-coil domain, and the carboxyl-terminal Rab GTPase domain. A common feature of large Rab GTPases is that they express several isoforms in cells. For instance, Rab44’s two isoforms have similar functions, but exhibit differential localization. The long form of Rab45 (Rab45-L) is abundantly distributed in epithelial cells. The short form of Rab45 (Rab45-S) is predominantly present in the testes. Both Rab46 (CRACR2A-L) and the short isoform lacking the Rab domain (CRACR2A-S) are expressed in T cells, whereas Rab46 is only distributed in endothelial cells. Although evidence regarding the function of large Rab GTPases has been accumulating recently, there Citation: Tsukuba, T.; Yamaguchi, Y.; are only a limited number of studies.
    [Show full text]
  • New Approach for Untangling the Role of Uncommon Calcium-Binding Proteins in the Central Nervous System
    brain sciences Review New Approach for Untangling the Role of Uncommon Calcium-Binding Proteins in the Central Nervous System Krisztina Kelemen * and Tibor Szilágyi Department of Physiology, Doctoral School, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Târgu Mures, , Romania; [email protected] * Correspondence: [email protected]; Tel.: +40-746-248064 Abstract: Although Ca2+ ion plays an essential role in cellular physiology, calcium-binding proteins (CaBPs) were long used for mainly as immunohistochemical markers of specific cell types in different regions of the central nervous system. They are a heterogeneous and wide-ranging group of proteins. Their function was studied intensively in the last two decades and a tremendous amount of informa- tion was gathered about them. Girard et al. compiled a comprehensive list of the gene-expression profiles of the entire EF-hand gene superfamily in the murine brain. We selected from this database those CaBPs which are related to information processing and/or neuronal signalling, have a Ca2+- buffer activity, Ca2+-sensor activity, modulator of Ca2+-channel activity, or a yet unknown function. In this way we created a gene function-based selection of the CaBPs. We cross-referenced these findings with publicly available, high-quality RNA-sequencing and in situ hybridization databases (Human Protein Atlas (HPA), Brain RNA-seq database and Allen Brain Atlas integrated into the HPA) and created gene expression heat maps of the regional and cell type-specific expression levels of the selected CaBPs. This represents a useful tool to predict and investigate different expression patterns and functions of the less-known CaBPs of the central nervous system.
    [Show full text]
  • Number 3 March 2015
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST -CNRS Volume 19 - Number 3 March 2015 The PDF version of the Atlas of Genetics and Cytogenetics in Oncology and Haematology is a reissue of the original articles published in collaboration with the Institute for Scientific and Technical Information (INstitut de l’Information Scientifique et Technique - INIST) of the French National Center for Scientific Research (CNRS) on its electronic publishing platform I-Revues. Online and PDF versions of the Atlas of Genetics and Cytogenetics in Oncology and Haematology are hosted by INIST-CNRS. Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST -CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It presents structured review articles (“cards”) on genes, leukaemias, solid tumours, cancer-prone diseases, and also more traditional review articles (“deep insights”) on the above subjects and on surrounding topics. It also present case reports in hematology and educational items in the various related topics for students in Medicine and in Sciences. Editorial correspondance Jean-Loup Huret Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France tel +33 5 49 44 45 46 [email protected] or [email protected] Staff Mohammad Ahmad, Mélanie Arsaban, Marie-Christine Jacquemot-Perbal, Vanessa Le Berre, Anne Malo, Carol Moreau, Catherine Morel-Pair, Laurent Rassinoux, Alain Zasadzinski. Philippe Dessen is the Database Director (Gustave Roussy Institute – Villejuif – France).
    [Show full text]
  • Transcriptomic Changes Resulting from STK32B Overexpression Identifies Pathways Potentially Relevant to Essential Tremor
    bioRxiv preprint doi: https://doi.org/10.1101/552901; this version posted May 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Transcriptomic changes resulting from 2 STK$%B overexpression identifies pathways 3 potentially relevant to essential tremor 4 Calwing Liao.,0, Faezeh Sarayloo.,0, Veikko Vuokila0, Daniel Rochefort0, Fulya Akçimen.,0, 5 Simone Diamond0, Alexandre D. Laporte0, Dan Spiegelman0, Qin HeJ, Hélène Catoire0, Patrick A. 6 Dion0,O, Guy A. Rouleau.,0,O 7 8 .Department of Human GeneticS, McGill University, Montréal, Quebec, Canada 9 0Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada. 10 JDepartment of Biomedical ScienceS, Université de Montréal, Montréal, Quebec, Canada 11 ODepartment of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada 12 13 Corresponding Author: 14 Dr. Guy A. Rouleau, MD, PhD, FRCPC, OQ 15 Department of Neurology and Neurosurgery 16 McGill University 17 Montréal, Québec, Canada 18 HJA 0BO 19 E-mail: [email protected] 20 21 Keywords: STK$%B, eSSential tremor, transcriptome, FUS 22 Conflict of Interests: All authors report no conflict of intereStS. 23 Funding Sources: Canadian InstituteS of Health ReSearch 24 bioRxiv preprint doi: https://doi.org/10.1101/552901; this version posted May 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Risk Factors and Epigenetic Markers of Left Ventricular Diastolic Dysfunction with Preserved Ejection Fraction in a Community-Based Elderly Chinese Population
    Clinical Interventions in Aging Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Risk Factors And Epigenetic Markers Of Left Ventricular Diastolic Dysfunction With Preserved Ejection Fraction In A Community-Based Elderly Chinese Population This article was published in the following Dove Press journal: Clinical Interventions in Aging Wei Wang1,2 Purpose: Left ventricular diastolic dysfunction with preserved ejection fraction (LVDD-PEF) is Yi Zhang3 an early-stage manifestation but poorly understood in the process of heart failure. This study was Runzi Wang 1,2 designed to investigate risk factors and epigenetic markers for predicting LVDD-PEF. Yeshaswi Shrestha1,2 Patients and methods: A community-based study in 1568 residents over 65 years was ’ Yawei Xu 3 conducted in Shanghai, People s Republic of China, from June 2014 to August 2015. Echocardiography was performed to diagnose LVDD-PEF. DNA methylation by whole- Luying Peng1,4,5 genome bisulfite sequencing was used to determine those potential epigenetic markers Jie Zhang1,2 1,2 contributing to LVDD-PEF. Jue Li Results: A total of 177 participants (11.3%) were diagnosed with LVDD-PEF, and higher 1,2 Lijuan Zhang prevalence in females than in males (15.0% vs 6.5%, P<0.001). Multivariate logistic regres- 1Key Laboratory of Arrhythmias of the sion analysis indicated that female sex (OR 2.46, 95% CI 1.47–4.13), body mass index Ministry of Education, Tongji University (BMI) (OR 1.09, 95% CI 1.04–1.14), pulse pressure (PP) (OR 1.03, 95% CI 1.01–1.05) and School of Medicine, Shanghai 200092, – fi People’s Republic of China; 2Institute of carotid intima-media thickness (CIMT) (OR 4.20, 95% CI 1.40 12.55) showed a signi cant Clinical Epidemiology and Evidence-Based association with LVDD-PEF.
    [Show full text]
  • CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses
    CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses This information is current as Jin Seok Woo, Sonal Srikanth, Kyun-Do Kim, Heidi of September 24, 2021. Elsaesser, Jing Lu, Matteo Pellegrini, David G. Brooks, Zuoming Sun and Yousang Gwack J Immunol 2018; 201:1174-1185; Prepublished online 9 July 2018; doi: 10.4049/jimmunol.1800659 Downloaded from http://www.jimmunol.org/content/201/4/1174 Supplementary http://www.jimmunol.org/content/suppl/2018/07/06/jimmunol.180065 Material 9.DCSupplemental http://www.jimmunol.org/ References This article cites 52 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/201/4/1174.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts Errata An erratum has been published regarding this article. Please see next page or: /content/203/1/293.full.pdf The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • Download the 2017-18 Annual Report
    Molecular Biology Institute ANNUAL REPORT 2017-2018 (310) 825-1018 mbi.ucla.edu UCLA Boyer Hall [email protected] MOLECULAR BIOLOGY INSTITUTE REMEMBERING PAUL BOYER MBI DIRECTOR’S REPORT 1 MBI COMMITTEES 3 MBI ADMINISTRATIVE SUPPORT STAFF ACTIVITIES Administrative Services 4 Building Management 5 MBI PROGRAMS & EVENTS The David S. Sigman Memorial Lectureship & Symposium 7 The Audree Fowler Fellows in Protein Science 8 The Jules Brenner Achievement Fellowship in Molecular Biology 9 Boyer/Parvin Postdoctoral Research Awards 10 Thursday Seminar Series 11 MBI Interdisciplinary Faculty Seminars 14 MBI Annual Retreat & Research Conference 18 Biotechnology Edge Workshop 16 Focus on Imaging Workshop 17 Mouse Genome Informatics Workshop 18 MBI FACULTY RESEARCH & PROFESSIONAL ACTIVITIES Newly Appointed Members 19 Honors & Professional Awards 22 Service on UCLA Committees 23 Service on External Committees 27 Patents Issued 32 Visiting Faculty & Scholars 33 MBI PARTNERS IN BOYER HALL Institute for Quantitative & Computational Biology (QCBio) 35 The QCBio Collaboratory 35 UCLA-DOE Institute 35 Fermentation Core Facility 36 GRADUATE PROGRAMS Molecular Biology Interdepartmental Ph.D. Program (MBIDP) 37 Whitcome Pre-doctoral Training Program 54 MEMBER PUBLICATIONS MBI Faculty Publications 55 PAUL D. BOYER 1918 - 2018 REMEMBERING WITH GRATITUDE PAUL D. BOYER 1918 - 2018 Dear Colleagues, This year will be forever memorable in the history of our Institute because it marks the passing of our beloved Paul Boyer. His many scientific and academic accomplishments have been highlighted in several journals and it has been wonderful to hear so many colleagues speak about how much Dr. Boyer meant to them. We are grateful for his vision, his collegiality, his commitment to scientific excellence and his optimistic spirit, all of which became part of the culture of our institute.
    [Show full text]
  • Detection of H3k4me3 Identifies Neurohiv Signatures, Genomic
    viruses Article Detection of H3K4me3 Identifies NeuroHIV Signatures, Genomic Effects of Methamphetamine and Addiction Pathways in Postmortem HIV+ Brain Specimens that Are Not Amenable to Transcriptome Analysis Liana Basova 1, Alexander Lindsey 1, Anne Marie McGovern 1, Ronald J. Ellis 2 and Maria Cecilia Garibaldi Marcondes 1,* 1 San Diego Biomedical Research Institute, San Diego, CA 92121, USA; [email protected] (L.B.); [email protected] (A.L.); [email protected] (A.M.M.) 2 Departments of Neurosciences and Psychiatry, University of California San Diego, San Diego, CA 92103, USA; [email protected] * Correspondence: [email protected] Abstract: Human postmortem specimens are extremely valuable resources for investigating trans- lational hypotheses. Tissue repositories collect clinically assessed specimens from people with and without HIV, including age, viral load, treatments, substance use patterns and cognitive functions. One challenge is the limited number of specimens suitable for transcriptional studies, mainly due to poor RNA quality resulting from long postmortem intervals. We hypothesized that epigenomic Citation: Basova, L.; Lindsey, A.; signatures would be more stable than RNA for assessing global changes associated with outcomes McGovern, A.M.; Ellis, R.J.; of interest. We found that H3K27Ac or RNA Polymerase (Pol) were not consistently detected by Marcondes, M.C.G. Detection of H3K4me3 Identifies NeuroHIV Chromatin Immunoprecipitation (ChIP), while the enhancer H3K4me3 histone modification was Signatures, Genomic Effects of abundant and stable up to the 72 h postmortem. We tested our ability to use H3K4me3 in human Methamphetamine and Addiction prefrontal cortex from HIV+ individuals meeting criteria for methamphetamine use disorder or not Pathways in Postmortem HIV+ Brain (Meth +/−) which exhibited poor RNA quality and were not suitable for transcriptional profiling.
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Vigorous Physical Activity Is Associated with Lower Risk of Metastatic–Lethal Progression in Prostate Cancer and Hypomethylati
    Published OnlineFirst November 21, 2018; DOI: 10.1158/1055-9965.EPI-18-0622 Research Article Cancer Epidemiology, Biomarkers Vigorous Physical Activity Is Associated with & Prevention Lower Risk of Metastatic–Lethal Progression in Prostate Cancer and Hypomethylation in the CRACR2A Gene James Y. Dai1,2, Bo Wang3, Xiaoyu Wang1, Anqi Cheng2, Suzanne Kolb1, Janet L. Stanford1,4, and Jonathan L. Wright1,5 Abstract Background: There is preliminary evidence linking physical prostatectomy as primary treatment and tumor tissue avail- activity to better prostate cancer outcomes, though the molec- able, a differentially methylated region (DMR) was identified ular mechanisms underlying this association are not clear. (family-wise error rate ¼ 0.03, hypomethylated in the weekly Methods: In a Seattle-based cohort of patients diagnosed exercise group), with 9 methylation probes located in the with clinically localized prostate cancer and prospective fol- promoter region of CRACR2A. This gene encodes a calcium low-up for outcomes (n ¼ 1,354), we studied the association binding protein involved in innate immune response. The between self-reported vigorous physical activity and prostate methylation level of the nine CpGs was inversely correlated cancer progression to a metastatic–lethal phenotype. A subset with CRACR2A gene expression (average correlation coeffi- of patients had prostate cancer tissue samples available for cient ¼ –0.35). investigating DNA methylation (Infinium HumanMethyla- Conclusions: Vigorous physical activity before diagnosis is tion450
    [Show full text]
  • Onco-Proteogenomic Exploration of Variant Peptide Detection in Disease Models and Clinical Specimens
    Onco-proteogenomic exploration of variant peptide detection in disease models and clinical specimens by Lampros Dimitrakopoulos A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Laboratory Medicine and Pathobiology University of Toronto © Copyright by Lampros Dimitrakopoulos 2017 Onco-proteogenomic exploration of variant peptide detection in disease models and clinical specimens Lampros Dimitrakopoulos Doctor of Philosophy Laboratory Medicine and Pathobiology University of Toronto 2017 Abstract This thesis describes the efforts of integrating nucleotide sequencing results with mass spectrometry-based proteomic results to identify variants predicted from sequencing and being expressed at the proteome level within a proteogenomic framework. Specifically, the study was carried out in three levels. The first was a proof of concept study to demonstrate the feasibility of variant peptide detection in clinical specimens and reveal intrinsic strengths and weaknesses of the onco-proteogenomic pipeline. Subsequently, sequencing-predicted variants were tracked at the proteome level in cancer cell lines and breast cancer tissues. The results from both homogeneous and heterogeneous cell populations reveal the proportion of sequencing-predicted variant peptides detected at the proteome level, how different variant calling filtering criteria from sequencing raw data and alternative ways to search for variant peptides influence this number, a correlation between transcript abundance and variant peptide detection and how the translated mutant versions of the proteins may influence the observed phenotype. Overall, the results of the present dissertation provide promising evidence that the combination of the well-established sequencing technologies and the excellent capabilities of state of the art mass spectrometry instruments can effectively detect variant peptides in clinical specimens and that this approach has the potential to be optimized to harness its full potential and realize precision medicine translational applications.
    [Show full text]